IONQ Stock Analysis: Resuming the Uptrend After a Brief Correction
IONQ Inc., a trailblazer in quantum computing, specializes in developing and manufacturing quantum computers. Founded in 2015 by Christopher Monroe and Jung Sang Kim, the company is based in College…
Robinhood (NASDAQ: HOOD) Enters Wave (III) Final Stage
Robinhood (NASDAQ: HOOD) rallied more than 300% since April 2025 breaking into new all time highs. In our previous article, we explained the bullish sequence taking place within the weekly cycle leading…
TXN Elliott Wave View: Dip Approaches Blue Box Buying Zone
After it completed a 55% rally from April 2025 to July 2025, TXN is correcting the impulse rally. At the extreme of the current pullback, buyers can find new entry.…
CRWD in Final Stage: One More High Could Trigger Market Correction
CrowdStrike (CRWD) leads AI-powered cybersecurity with strong financial results and growing market presence. By mid-2025, its market value passed $104 billion. This shows investor trust, even with ongoing net losses.…
Dow Futures (YM) Resumes Upward Drive in Impulsive Formation
The short-term Elliott Wave analysis for Dow Futures (YM) indicates a cycle from the 1 August 2025 low is forming an impulse. The wave 1 peaked at 45,841, followed by…
SPY Elliott Wave Outlook: Wave (3) Nearing Termination
The short-term Elliott Wave outlook for the S&P 500 ETF (SPY) highlights a cycle starting from the August 1 low. This cycle is unfolding as a diagonal and nears completion.…
Biotech Surge: XBI Ends Correction and Rallies as Expected
The SPDR S&P Biotech ETF (XBI) draws investors who seek high-risk, high-reward exposure to the biotech sector. In late 2025, investor sentiment remains cautiously optimistic. This reflects both strong opportunities…
Elliott Wave Insights for QQQ Nearing wave (3) Termination at 589
The short-term Elliott Wave analysis for the Nasdaq 100 Index ETF (QQQ) indicates it is approaching the completion of wave (3) from its April 2025 low. This wave (3) unfolds…
Alnylam (ALNY) Should Rally Into $479-$494 Before Correction Start
Alnylam Pharmaceuticals Inc., (ALNY) discovers, develops & commercializes therapeutics based on ribonucleic acid interference. It comes under Healthcare – Biotech sector & trades as “ALNY” ticker at Nasdaq. ALNY is…
